Literature DB >> 8405003

Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome.

H Gerlach1, R Rossaint, D Pappert, K J Falke.   

Abstract

Inhalation of nitric oxide (NO), an endogenous vasodilator, was recently described to reduce pulmonary vascular resistance, and to improve arterial oxygenation by selective vasodilation of ventilated areas in patients with adult respiratory distress syndrome (ARDS). We describe the time-course and dose-response of initial short-term NO inhalation in 12 patients with ARDS. Enhanced oxygenation was achieved within 1-2 min after starting NO inhalation; after inhalation, baseline conditions were re-achieved within 5-8 min. Effective doses for improvement of oxygenation [baseline: PaO2 = 10.2 +/- 2.5 KPa (76.4 +/- 18.7 mmHg)] were low: ED50 was about 100 ppb--a concentration similar to the atmosphere. NO doses of more than 10 ppm [10 ppm NO: PaO2 = 17.3 +/- 3.3 KPa (129.4 +/- 25.1 mmHg)] re-worsen the arterial oxygenation. The ED50 for reduction of mean pulmonary artery pressure was 2-3 ppm. This indicates that inhalation of NO for improvement of oxygenation in severe ARDS should be performed using lower doses, with lower risk of toxic side effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405003     DOI: 10.1111/j.1365-2362.1993.tb00797.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  46 in total

Review 1.  Nasal nitric oxide in man.

Authors:  J O Lundberg; E Weitzberg
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Successful treatment of acute respiratory distress syndrome after hysterectomy for life-threatening atonic bleeding by inhaled nitric oxide.

Authors:  Ayaka Fujita; Eiji Hashiba; Noriaki Otomo; Masatoshi Muraoka; Futoshi Kimura; Kazuyoshi Hirota
Journal:  J Anesth       Date:  2011-06-03       Impact factor: 2.078

Review 3.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

4.  [Inhaled nitric oxide for the treatment of ARDS].

Authors:  H Lohbrunner; M Deja; T Busch; C D Spies; R Rossaint; U Kaisers
Journal:  Anaesthesist       Date:  2004-08       Impact factor: 1.041

Review 5.  [Management of patients with pulmonary hypertension].

Authors:  B Preckel; S Eberl; J Fräßdorf; M W Hollmann
Journal:  Anaesthesist       Date:  2012-07       Impact factor: 1.041

6.  Adjunctive therapy with inhaled nitric oxide for severe acute chest syndrome in patients with sickle cell disease.

Authors:  Hermann Wrigge; Eduardo L V Costa; Thilo Busch
Journal:  Intensive Care Med       Date:  2015-10-02       Impact factor: 17.440

7.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

8.  Aerosolized prostacyclin and inhaled nitric oxide in septic shock--different effects on splanchnic oxygenation?

Authors:  O Eichelbrönner; H Reinelt; H Wiedeck; M Mezödy; R Rossaint; M Georgieff; P Radermacher
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

9.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

10.  Combined effects of NO inhalation and intravenous PGF2 alpha on pulmonary circulation and gas exchange in an ovine ARDS model.

Authors:  H Kobayashi; N Tanaka; M Winkler; W M Zapol
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.